JP2009526750A5 - - Google Patents

Download PDF

Info

Publication number
JP2009526750A5
JP2009526750A5 JP2008547703A JP2008547703A JP2009526750A5 JP 2009526750 A5 JP2009526750 A5 JP 2009526750A5 JP 2008547703 A JP2008547703 A JP 2008547703A JP 2008547703 A JP2008547703 A JP 2008547703A JP 2009526750 A5 JP2009526750 A5 JP 2009526750A5
Authority
JP
Japan
Prior art keywords
seq
glp
composition
mimetibody
animal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008547703A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009526750A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/062223 external-priority patent/WO2007076319A2/en
Publication of JP2009526750A publication Critical patent/JP2009526750A/ja
Publication of JP2009526750A5 publication Critical patent/JP2009526750A5/ja
Pending legal-status Critical Current

Links

JP2008547703A 2005-12-22 2006-12-18 Glp−1アゴニスト、組成物、方法および使用 Pending JP2009526750A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75282605P 2005-12-22 2005-12-22
PCT/US2006/062223 WO2007076319A2 (en) 2005-12-22 2006-12-18 Human glp-1 mimetibodies and compositions for treating obesity and related disorders, methods and uses

Publications (2)

Publication Number Publication Date
JP2009526750A JP2009526750A (ja) 2009-07-23
JP2009526750A5 true JP2009526750A5 (enExample) 2009-09-17

Family

ID=38218787

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008547703A Pending JP2009526750A (ja) 2005-12-22 2006-12-18 Glp−1アゴニスト、組成物、方法および使用

Country Status (4)

Country Link
EP (1) EP1968645A4 (enExample)
JP (1) JP2009526750A (enExample)
CA (1) CA2634784A1 (enExample)
WO (1) WO2007076319A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200843794A (en) * 2006-12-21 2008-11-16 Centocor Inc Use of long-acting GLP-1 receptor agonists to improve insulin sensitivity and lipid profiles
CN101918027A (zh) * 2007-11-02 2010-12-15 森托科尔奥索生物科技公司 半合成GLP-1肽-Fc融合构造、方法及其用途
US8580927B2 (en) 2008-01-31 2013-11-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Engineered antibody constant domain molecules
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
EP3947451A1 (en) 2019-04-01 2022-02-09 Novo Nordisk A/S Antibodies directed against liraglutide and use thereof
US20230183335A1 (en) 2020-06-03 2023-06-15 Københavns Universitet Glp1r agonist nmdar antagonist conjugates

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005231359A1 (en) * 2004-03-31 2005-10-20 Centocor, Inc. Human GLP-1 mimetibodies, compositions, methods and uses

Similar Documents

Publication Publication Date Title
JP2008525477A5 (enExample)
US9944687B2 (en) Compounds and their effects on feeding behaviour
US8450459B2 (en) IL-21 derivatives and variants
ES2732291T3 (es) Péptidos terapéuticos
EP1871794B1 (en) Modified pyy(3-36) peptides and their effects on feeding behavior
US20180280480A1 (en) Compositions and peptides having dual glp-1r and glp-2r agonist activity
AU2019256245B2 (en) Acylated GLP-1 derivative
AU2019218147B2 (en) FGF21 variant, fusion protein and application thereof
EP2025684A1 (en) Glucagon analogues
KR20070004078A (ko) 인간 glp-1 모방체, 조성물, 방법 및 용도
ME02185B (me) Anti-il-6 antitela, preparati, postupci pripreme i upotrebe
JP2005512522A5 (enExample)
TW200843794A (en) Use of long-acting GLP-1 receptor agonists to improve insulin sensitivity and lipid profiles
TW201741333A (zh) Mic-1化合物及其用途
CN111163795A (zh) 用于治疗肥胖症的mic-1和glp-1
KR101661332B1 (ko) 글루카곤 유사 펩타이드-1 수용체 항진제를 포함하는 근감소증 치료용 약학 조성물
JP2009526750A5 (enExample)
RU2012106302A (ru) Аналоги инсулиноподобного фактора роста-1 (igf-1), содержащие аминокислотную замену в положении 59
Mak et al. Preparation of potent leptin receptor antagonists and their therapeutic use in mouse models of uremic cachexia and kidney fibrosis
JP2021505656A (ja) グルカゴン様ペプチド
EP3281951A1 (en) Insulinotropic peptide derivative with modified n-terminal charge
JP2008546373A5 (enExample)
CN111727198A (zh) Pyy类似物
CN118401250A (zh) 用于治疗肥胖症的il-4衍生肽
ES2324306T3 (es) Uso de il-17f para el tratamiento y/o la prevencion de enfermedades neurologicas.